Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $2.2 million.

  • Theravance Biopharma's Accounts Payables rose 5220.08% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 5220.08%. This contributed to the annual value of $2.2 million for FY2024, which is 4711.29% up from last year.
  • Latest data reveals that Theravance Biopharma reported Accounts Payables of $2.2 million as of Q3 2025, which was up 5220.08% from $1.7 million recorded in Q2 2025.
  • Theravance Biopharma's Accounts Payables' 5-year high stood at $10.7 million during Q2 2021, with a 5-year trough of $1.5 million in Q3 2024.
  • Over the past 5 years, Theravance Biopharma's median Accounts Payables value was $2.2 million (recorded in 2024), while the average stood at $3.3 million.
  • In the last 5 years, Theravance Biopharma's Accounts Payables plummeted by 7790.46% in 2022 and then surged by 7635.76% in 2023.
  • Theravance Biopharma's Accounts Payables (Quarter) stood at $3.1 million in 2021, then plummeted by 49.84% to $1.6 million in 2022, then decreased by 1.93% to $1.5 million in 2023, then soared by 47.11% to $2.2 million in 2024, then fell by 1.29% to $2.2 million in 2025.
  • Its Accounts Payables stands at $2.2 million for Q3 2025, versus $1.7 million for Q2 2025 and $2.4 million for Q1 2025.